FDA accelerated approval path needs improvement, says ICER
Pharmaphorum
The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.
Lilly says Foundayo safety confirmed in ACHIEVE-4 trial
Pharmaphorum
Eli Lilly’s ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.
Revolution doubles stock offering target to $2B following pancreatic cancer win
BioSpace
After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt o
Beeline raises $300m for BMS drugs, and other biofinancings
Pharmaphorum
Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.
Most patients “won’t see benefit” with Alzheimer’s drugs
Pharmaphorum
A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.
Terremoto wins $108m in Series C to drive cancer and rare disease programmes
Pharmaceutical Technology
Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Pharmaceutical Business Review
This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim’s DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Pharmaceutical Technology
Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.
Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers
BioPharma Dive
Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.
Travere wins long-awaited approval for kidney disease drug
BioPharma Dive
The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity believed to be worth more than $1 billion annually.
FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)
Big Molecule Watch
On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.
Lilly to acquire CrossBridge Bio for up to $300m
Pharmaceutical Technology
Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.
Lilly to acquire CrossBridge Bio for up to $300m
Pharmaceutical Business Review
The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer.
Adcendo secures $75m in Series C funding for ADC development
Pharmaceutical Technology
Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.
Adcendo secures $75m in Series C funding for ADC development
Pharmaceutical Business Review
The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of th
J&J sets the tone for Q1 earnings with strong oncology growth
Pharmaceutical Technology
Off the back of J J’s positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde
Amazon launches its AI drug discovery platform
Pharmaphorum
Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that combines in silico and wet-lab work in a single application.
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
BioSpace
The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.
Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico
BioSpace
After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.
Parkinson’s charity partners Biognosys on biomarker project
Pharmaphorum
A new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson’s that has emerged as a major drug target in the disease.